IPP Bureau

Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis
Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

By IPP Bureau - June 12, 2022

Amarex Clinical Research guides its client to phase II of FDA trials

Isotopia and CPDC deliver first doses of n.c.a. Lu-177 to North American customers
Isotopia and CPDC deliver first doses of n.c.a. Lu-177 to North American customers

By IPP Bureau - June 12, 2022

The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America

Cantourage and Clever leaves intensify partnership for distribution of medical cannabis in Germany
Cantourage and Clever leaves intensify partnership for distribution of medical cannabis in Germany

By IPP Bureau - June 12, 2022

Cantourage introduces second Clever Leaves medical cannabis product to the German market

China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer

By IPP Bureau - June 12, 2022

Tislelizumab is now approved in nine indications in China

Modi Inaugurates hospital complex and CoE in South Gujarat
Modi Inaugurates hospital complex and CoE in South Gujarat

By IPP Bureau - June 11, 2022

Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools

Eppendorf India inaugurates pipette laboratory and service hub in Chennai
Eppendorf India inaugurates pipette laboratory and service hub in Chennai

By IPP Bureau - June 11, 2022

SPLASH also houses the tools’ calibration for epMotion, Eppendorf automated liquid handling workstations.

TaCa Healthcare expands its operations to Telangana and Andhra Pradesh
TaCa Healthcare expands its operations to Telangana and Andhra Pradesh

By IPP Bureau - June 11, 2022

Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states

Takeda’s dengue vaccine candidate offers protection against dengue fever in clinical trial
Takeda’s dengue vaccine candidate offers protection against dengue fever in clinical trial

By IPP Bureau - June 11, 2022

TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union

Sanyou Biopharmaceuticals launches Super-Trillion Antibody Libraries
Sanyou Biopharmaceuticals launches Super-Trillion Antibody Libraries

By IPP Bureau - June 11, 2022

New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets

AIkido Pharma appoints Soo Yu as Director
AIkido Pharma appoints Soo Yu as Director

By IPP Bureau - June 11, 2022

New Director supports NASDAQ rule on diversity

Illumina appoints Joydeep Goswami as Interim CFO
Illumina appoints Joydeep Goswami as Interim CFO

By IPP Bureau - June 11, 2022

Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.

AeroSafe Global appointment Jessica Cao as Sr VP (Marketing)
AeroSafe Global appointment Jessica Cao as Sr VP (Marketing)

By IPP Bureau - June 11, 2022

Company hires life science veteran Jessica Cao to join management team

Nippon Express launches ultra-low temperature-controlled service for pharma industry
Nippon Express launches ultra-low temperature-controlled service for pharma industry

By IPP Bureau - June 11, 2022

Nippon Express has provided a pharmaceutical distribution platform with strict temperature control in two ranges -- 2 C to 8 C

Marinus expands enrollment criteria to support recruitment in Phase 3 RAISE Trial in refractory status epilepticus
Marinus expands enrollment criteria to support recruitment in Phase 3 RAISE Trial in refractory status epilepticus

By IPP Bureau - June 10, 2022

Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.

Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies
Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies

By IPP Bureau - June 10, 2022

During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.

Latest Stories

Interviews

Packaging